Zelluna ASA’s shares fell 4.46% to $21.40 on Tuesday after the company disclosed initial clinical data for its lead TCR-NK cancer therapy, ZI-MA4-1, despite reporting no dose-limiting toxicities or serious adverse events.
The first patient in the Phase 1 ZIMA-101 trial completed all three planned doses on Days 1, 4, and 8, followed by the protocol-defined safety observation period, the company said in its Q2 2026 business update. An Independent Data Monitoring Committee reviewed the data and recommended continued enrollment at Dose Level 1.
ZI-MA4-1 targets MAGE-A4, an antigen expressed in 25–70% of certain solid tumors, including lung, ovarian, sarcoma, and head and neck cancers. The company estimates the target addresses over 50,000 treatable patients in North America and Western Europe. Dose escalation is expected to conclude in the first half of 2027, with dose expansion to follow. Updated clinical data is anticipated at international conferences later this year, including ESMO 2026.
Zelluna also outlined its preclinical pipeline, including ZI-KL1-1 targeting KK-LC-1, with in-vitro data expected by year-end, and ZI-PR-1 targeting PRAME, currently in discovery.
Financially, Zelluna reported NOK 86 million in cash and cash equivalents at the end of Q2 2026, supported by NOK 58.2 million in gross proceeds from a private placement and retail offering, plus a NOK 16 million grant from the Research Council of Norway. The company posted an operating loss of NOK 20 million for the quarter and NOK 40 million year-to-date, with negative operating cash flow of NOK 20 million in Q2.
CEO Namir Hassan described the quarter as a defining moment for Zelluna, noting the transition into clinical data generation as a potential value inflection point for the TCR-NK platform. The company employs 15 full-time equivalents as of quarter-end.
The update follows recent high-value deals in the TCR-NK space, including Lilly’s $7 billion acquisition of Kelonia in April 2026, AbbVie’s $2.1 billion deal with Capstan Therapeutics, and AstraZeneca’s $1 billion investment in EsoBiotec.
